当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Phung Thi Huyen
Objective:To evaluate response rate, time to disease progression and the toxicity of vinorelbine monotherapy in second line treatment of patients with recurrent and metastaticbreast cancerat Viet Nam National Cancer hospital.
Patients and Methods:Prospective combined retrospective descriptive study. The study based on 71 patients with breast cancer recurrence and metastasis after radical treatment with Taxane/ Anthracycline frist lines at Viet Nam National Cancer Hospital from 4/2015 to 6/2018 were treated with weekly Vinorelbine 25 mg/m2 IV or Vinorelbine 60mg/m2 PO or combination on day 1 every week, at least 6 weeks.
Results:The presence of recurrent metastasis most common of this group in the second year, third year after radical treatment 57,8%. There was 15,5% of patients with metastatic recurrence after 5 years. Free – recurrence survival was 21 ± 10,44 months. There was 30,1% of the cases of recurrence metastasis without clinical symptoms. In all cases of bone pain symptoms, the most common, accounting of 40,3%. Most patients with recurrent metastatic had multiple locations at the time of diagnosis (70,4% ). Metastase bone, lung, liver were most commonly as 61,9%; 46,5%; 40%, respectively. Complete response rate is 4,2%, partial response of 30,6%. In which 59,2% patients had no response, 38,1% stable disease and 21,1% progress disease. Time to disease progression is 7,2 months. There was no significant difference in RR and PFS was observed between the arms. Grade 3 and 4 hematologic and non-hematologic toxicity rate were low. The rate of hematologic toxicity were significantly higher in Vinorelbine IV with the rates of leukopenia and neutropenia were 43,2% and 41,5%, non-hematologic toxicity rate were significantly higher in Vinorelbine OP with the rates of nausea/ vomiting; diarrhoea; mucositis were 45,2%; 42,1% and 42,1%.
Conclusion:The regimen has good results and safe.